これまでの研究発表（業績）一覧

＜英文原著＞

1. Samuraki M, Matsunari I, Yoshita M, Shima K, Noguchi-Shinohara M, Hamaguchi T, Ono K, Yamada M. Cerebral amyloid angiopathy-related microbleeds correlate with glucose metabolism and brain volume in Alzheimer's disease. J Alzheimers Dis 48, 517-528, 2015.
2. Takahashi R, Ono K, Takamura Y, Mizuguchi M, Ikeda T, Nishijo H, Yamada M. Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity. *J Neurochem* 134: 943-955, 2015.
3. Sakai K, Ikeda Y, Ishida C, Matsumoto Y, Ono K, Iwasa K, Yamada M. Inclusion body myositis with granuloma formation in muscle tissue. Neuromuscul Disord 25, 706-712, 2015.
4. Noguchi-Shinohara M, Ono K, Hamaguchi T, Iwasa K, Nagai T, Kobayashi S, Nakamura H, Yamada M. Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial. *PLoS One* 10: e0126422, 2015.
5. Wang D, Ho L, Faith J, Ono K, Janle EM, Lachcik PJ, Cooper BR, Jannasch AH, D'Arcy BR, Williams BA, Ferruzzi MG, Levine S, Zhao W, Dubner L, Pasinetti GM. Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease β-amyloid oligomerization. *Mol Nutr Food Res* 59: 1025-1040, 2015.
6. Takahashi R, Ono K, Shibata S, Nakamura K, Komatsu J, Ikeda Y, Ikeda T, Samuraki M, Sakai K, Iwasa K, Kayano D, Yamada M. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area. *J Neurol Sci* 345: 231-235, 2014.
7. Wang J, Varghese M, Ono K, Yamada M, Levine S, Tzavaras N, Gong B, Hurst WJ, Blitzer RD, Pasinetti GM. Cocoa extracts reduce oligomerization of amyloid-β: implications for cognitive improvement in Alzheimer's disease. *J Alzheimers Dis* 41: 643-650, 2014.
8. Wang J, Land D, Ono K, Galvez J, Zhao W, Vempati P, Steele JW, Cheng A, Yamada M, Levine S, Mazzola P, Pasinetti GM. Molecular topology as novel strategy for discovery of drugs with Aβ lowering and anti-aggregation dual activities for Alzheimer's disease. *PLoS One* 9: e92750.
9. Iwasa K, Yoshikawa H, Samuraki M, Shinohara M, Hamaguchi T, Ono K, Nakamura H, Yamada M. Myasthenia gravis: Predictive factors associated with the synchronized

elevation of anti-acetylcholine receptor antibody titer in Kanazawa, Japan. *J Neuroimmunol* 267: 97-101.

10. Ono K, Takahashi R, Ikeda T, Mizuguchi M, Hamaguchi T, Yamada M. Exogenous amyloidogenic proteins function as seeds in amyloid β-protein aggregation *Biochim Biophys Acta (Molecular Basis of Disease)* 1842: 646-653, 2014.
11. Takamura Y*, Ono K*, Matsumoto J, Yamada M, Nishijo H. Effects of the neurotrophic agent T-817MA on oligomeric amyloid β-induced deficits in long-term potentiation in the hippocampal CA1 subfield. *Neurobiol Aging* 35, 532-536, 2014. *equally contributed authors.
12. Ono K, Takasaki J, Takahashi R, Ikeda T, Yamada M. Effects of anti-parkinsonian agents on β-amyloid and α-synuclein oligomer formation in vitro. *J Neurosci Res* 91, 1371-1381, 2013.
13. Wang J, Zhao Z, Lin E, Zhao W, Qian X, Freire D, Bilski AE, Cheng A, Vempati P, Ho L, Ono K, Yamada M, Pasinetti GM. Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease. *PLoS One* 8, e65232.
14. Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, Wang J, Sastre M, Ono K, Pasinetti GM. Nicotinamide riboside restores cognition through an up-regulation of PGC-1α regulated BACE1 degradation and mitochondrial gene expression in Alzheimer's mouse models. *Neurobiol Aging* 34: 1581-1588, 2013.
15. Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid β-protein and α-synuclein. *J Neurochem* 122: 883-890, 2012.
16. Takahashi R, Ono K, Ikeda T, Akagi A, Noto D, Nozaki I, Sakai K, Asakura H, Iwasa K, Yamada M. Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy. *Amyloid* 19: 129-132, 2012.
17. Hirohata M, Ono K, Takasaki JI, Takahashi R, Ikeda T, Morinaga A, Yamada M. Anti-amyloidogenic effects of soybean isoflavones in vitro: fluorescence spectroscopy demonstrating direct binding to Aβ monomers, oligomers and fibrils. *Biochim Biophys Acta (Molecular Basis of Disease)* 1822: 1316-1324, 2012.
18. Ono K, Li L, Takamura Y, Yoshiie Y, Zhu L, Han F, Mao X, Ikeda T, Takasaki J, Nishijo H, Takashima A, Teplow DB, Zagorski MG, Yamada M. Phenolic compounds prevent amyloid β-Protein oligomerization and synaptic dysfunction by site specific binding. *J Biol Chem* 287: 14631-14643, 2012.
19. Wang J, Ferruzzi MG, Ho L, Blount J, Janle EM, Gong B, Pan Y, Gowda N, Raftery D, Arrieta-Cruz I, Sharma V, Cooper B, Lobo J, Simon J, Zhang C, Cheng A, Qian X, Ono K,

Teplow DB, Pavlides C, Dixon R, Pasinetti G. Brain-Targeted Proanthocyanidin Metabolites for Alzheimer's Disease Treatment. *J Neurosci* 32: 5144-5150, 2012.

20. Ono K, Mochizuki H, Ikeda T, Nihira T, Takasaki J, Teplow DB, Yamada M. Effect of melatonin on α-synuclein self-assembly and cytotoxicity. *Neurobiol Aging* 33: 2172-85, 2012.
21. Shima K, Samuraki M, Chen WP, Yanase D, Noguchi-Shinohara M, Takeda N, Ono K, Yoshita M, Miyazaki Y, Matsuda H, Yamada M, Matsunari I. Posterior cingulate atrophy and metabolic decline in early stage Alzheimer's disease. *Neurobiol Aging* 33: 2006-2017, 2012.
22. Chen WP, Samuraki M, Shima K, Yanase D, Takeda N, Miyazaki Y, Ono K, Yoshita M, Nishimura S, Yamada M, Matsunari I. Effect of an age-mismatched and sex-mismatched normal database on diagnostic performance of ^{18}F-FDG PET for Alzheimer's Disease: The Ishikawa Brain Imaging Study. *Nucl Med Commun* 32: 1128-1133, 2011.
23. Takasaki J*, Ono K*, Yoshiike Y, Hirohata M, Ikeda T, Morinaga A, Takashima A, Yamada M. Vitamin A has antioligomerization effects on amyloid-β in vitro. *J Alzheimers Dis* 27: 271-280, 2011. *equally contributed authors.
24. Wang J, Ono K, Dickstein D, Arrieta-Cruz I, Zhao W, Qian X, Lamparello A, Ferruzzi MG, Pavlides C, Ho L, Hof P, Teplow DB, Pasinetti GM. Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. *Neurobiol Aging* 32: e1-e12, 2011.
25. Ono K, Takasaki J, Ikeda T, Yamada M. Familial Parkinson disease mutations influence α-synuclein assembly. *Neurobiol Dis* 43: 715-724, 2011.
26. Morinaga A, Ono K, Takasaki J, Ikeda T, Hirohata M, Yamada M. Effects of sex hormones on Alzheimer Disease-associated β-amyloid oligomer formation in vitro. *Exp Neurol* 228: 298-302, 2011.
27. Hirohata M, Ono K, Morinaga A, Ikeda T, Yamada M. Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation. *Neurosci Lett* 491: 48-52, 2011.
28. Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Shinohara M, Samuraki M, Yanase D, Yoshita M, Mastunari I, Yamada M. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET, and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic. *Dement Geriatr Cogn Disord* 30: 285-292, 2010.
29. Wang J, Santa-Maria I, Ho L, Ksiezak-Reding H, Ono K, Teplow DB, Pasinetti GM. Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's disease.

J Alzheimers Dis 22: 653-661, 2010.

30. Ono K, Condron MM, Teplow DB. Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid β-protein assembly and toxicity. *J Biol Chem* 285: 23186-23197, 2010.
31. Ikeda T, Ono K, Elashoff D, Margaret C, Noguchi-Shinohara M, Yoshita M, Teplow DB, Yamada M. Cerebrospinal fluid of Alzheimer patients promotes amyloid β-Protein oligomerization. *J Alzheimers Dis* 21: 81-86, 2010.
32. Hamaguchi T, Ono K, Murase A, Yamada M. Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid β aggregataion pathway. *Am J Pathol* 175: 2557-2565, 2009.
33. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid β-protein oligomers. *Proc Natl Acad Sci U S A* 106: 14745-14750, 2009.
34. Hirohata M, Ono K, Morinaga A, Ikeda T, Yamada M. Anti-aggregation and fibril-destabilizing effects of sex hormones on α-synuclein fibrils in vitro. *Exp Neurol* 217: 434-439, 2009.
35. Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, Nakagawa M, El-Agnaf OM, Yamada M. CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. *Brain Res* 1251: 1-6, 2009.
36. Ho L, Chen LH, Wang J, Zhao W, Talcott ST, Ono K, Teplow DB, Humala N, Cheng A, Percival SS, Ferruzzi M, Janle E, Weaver C, Dickstein DL, Pasinetti GM. Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration. *J Alzheimers Dis* 16: 59-72, 2009.
37. Zhao W, Wang J, Ho L, Ono K, Teplow DB, Pasinetti GM. Identification of antihypertensive drugs which inhibit amyloid β-protein oligomerization. *J Alzheimers Dis* 16: 49-57, 2009.
38. Ono K, Condron MM, Ho L, Wang J, Zhao W, Pasinetti GM, Teplow DB. Effects of grape seed-derived polyphenols on amyloid β-protein self-assembly and cytotoxicity. *J Biol Chem* 283: 32176-32187, 2008. *This article was selected as "**JBC Paper of the week**".*
39. Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, Humala N, Teplow DB, Pasinetti GM. Grape seed extract MegaNatural-AZ prevents Aβ oligomerization and attenuates cognitive deterioration in a mouse model of Alzheimer's disease. *J Neurosci* 28: 6388-6392, 2008.
40. Kato-Motozaki Y, Ono K, Shima K, Morinaga A, Machiya T, Nozaki I, Shibata-Hamaguchi A, Furukawa Y, Yanase D, Ishida C, Sakajiri K, Yamada M. Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. *J Neurol Sci*

270: 133-140, 2008.

41. Hirohata M, Ono K, Morinaga A, Yamada M. Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro. *Neuropharmacology* 54: 620-627, 2008.
42. Chen WP, Samuraki M, Yanase D, Shima K, Takeda N, Ono K, Yoshita M, Nishimura S, Yamada M, Matsunari I. Effect of sample size for normal database on diagnostic performance of brain FDG PET for the detection of Alzheimer's disease using automated image analysis. *Nucl Med Commun* 29: 270-276, 2008.
43. Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K, Yoshita M, Yamada M. Cerebrospinal fluid/serum IgG index is correlated with medial temporal lobe atrophy in Alzheimer's disease. *Dement Geriatr Cogn Disord* 25: 144-147, 2008.
44. Morinaga A, Hirohata M, Ono K, Yamada M. Estrogen has anti-amyloidogenic effects on Alzheimer's β-amyloid fibrils in vitro. *Biochem Biophys Res Commun* 359: 697-702, 2007.
45. Matsunari I, Samuraki M, Chen WP, Yanase D, Takeda N, Ono K, Yoshita M, Matsuda H, Yamada M, Kinuya S. Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. *J Nucl Med* 48: 1961-1970, 2007.
46. Ono K, Hirohata M., Yamada M. Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases. *Exp Neurol* 205: 414-424, 2007.
47. Ono K, Hirohata M, Yamada M. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for α-synuclein fibrils in vitro. *J Neurosci Res* 85: 1547-1557, 2007.
48. Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K, Yoshita M, Yamada M. Blood-brain barrier permeability correlates with medial temporal lobe atrophy, but not with amyloid-β protein transport across the blood-brain barrier in Alzheimer's disease. *Dement Geriatr Cogn Disord* 23: 241-245, 2007.
49. Hirohata M, Hasegawa K, Tsutsumi-Yasuhara S, Ohhashi Y, Ookoshi T, Ono K, Yamada M, Naiki H. Anti-amyloidogenic effect against Alzheimer's β-amyloid fibrils in vitro is exerted by preferential and reversible binding of flavonoids to the amyloid fibril structure. *Biochemistry* 46: 1888-1899, 2007.
50. Ono K & Yamada M. Vitamin A potently destabilizes preformed α-synuclein fibrils in vitro: implications for Lewy body diseases. *Neurobiol Dis* 25: 446-454, 2007.
51. Ono K, Noguchi-Shinohara M, Yoshita M, Naiki H, Yamada M. Cerebrospinal fluid of

Alzheimer's disease and dementia with Lewy bodies patients enhances α-synuclein fibril formation in vitro. *Exp Neurol* 203: 579-583, 2007.

52. Ono K, Noguchi-Shinohara M, Matsumoto Y, Samuraki M, Yanase D, Iwasa K, Naiki H, Yamada M. Blood-borne factors inhibit Alzheimer's β-amyloid fibril formation in vitro. *Exp Neurol* 202: 125-132, 2006.
53. Ono K & Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro. *J Neurochem* 97: 105-115, 2006.
54. Ono K, Hirohata M, Yamada M. α-Lipoic acid exhibits anti-amyloidogenicity for β-amyloid fibrils in vitro. *Biochem Biophys Res Commun* 341: 1046-1052, 2006.
55. Ono K, Hasegawa K, Naiki H, Yamada M. Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's β-amyloid fibrils in vitro. *Neurochem Int* 48: 275-285, 2006.
56. Ono K, Noguchi M, Matsumoto Y, Yanase D, Iwasa K, Naiki H, Yamada M. Cerebrospinal fluid of Alzheimer patients promotes β-amyloid fibril formation in vitro. *Neurobiol Dis* 20: 233-240, 2005.
57. Ono K, Hirohata M, Yamada M. Ferulic acid destabilizes preformed β-amyloid fibrils in vitro. *Biochem Biophys Res Commun* 336: 444-449, 2005.
58. Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. *Neuropharmacology* 49: 1088-1099, 2005.
59. Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, Yamada M. Decreased □-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. *J Neurol Sci* 237: 61-65, 2005.
60. Ono K, Hasegawa K, Naiki H, Yamada M. Preformed β-amyloid fibrils are destabilized by coenzyme Q10 in vitro. *Biochem Biophys Res Commun* 330: 111-116, 2005.
61. Ono K. Hasegawa K, Naiki H and Yamada M. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's β-amyloid fibrils in vitro. *Biochim Biophys Acta (Molecular Basis of Disease)* 1690: 193-202, 2004.
62. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. *Exp Neurol* 189: 380-392, 2004.
63. Ono K, Hasegawa K, Naiki H and Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. *J Neurosci Res* 75: 742-750, 2004.
64. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H and Yamada M. Potent

anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. *J Neurochem* 87: 172-181, 2003. *This article is among the "Top 10" for Journal of Neurochemistry articles published in 2003.*

65. Ono K, Hasegawa K, Yamada M, Naiki H. Nicotine breaks down preformed Alzheimer's β-amyloid fibrils in vitro. *Biol Psychiatry* 52: 880-886, 2002.
66. Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, Naiki H. Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's β-amyloid fibrils in vitro. *J Neurochem* 81: 434-440, 2002.
67. Hasegawa K, Ono K, Yamada M, Naiki H. Kinetic modeling and determination of reaction constants of Alzheimer's β-amyloid fibril extension and dissociation using surface plasmon resonance. *Biochemistry* 41: 13489-13498, 2002.

＜英文症例報告＞

1. Hayashi K, Iwasa K, Morinaga A, Ono K, Yamada M. Exacerbation of myasthenia gravis by intravenous peramivir. *Muscle Nerve* 51: 935-936, 2015.
2. Akagi A, Ono K, Hamaguchi T, Samuraki M, Nakada M, Shima Y, Oohata T, Yamada M. Neurolymphomatosis exhibiting repeated exacerbation and remission in both the peripheral and central nervous systems. *J Neurol Sci* 345: 267-268, 2014.
3. Sakai K, Ono K, Harada H, Shima K, Notoya M, Yamada M. Parkinson's disease showing progressive conduction aphasia. *Neurol Sci* 33: 399-402, 2012.
4. Komatsu J, Ono K, Yanase D, Samuraki M, Shima K, Kuwano R, Matsunari I, Yamada M. Imaging Findings of Familial Dementia with a Tau R406W Mutation. *Acta Neurol Berg* 111: 374-375, 2011.
5. Sakai K, Ono K, Okamoto Y, Murakami H, Yamada M. Cervical flexion myelopathy in a patient showing apparent long tract signs: a severe form of Hirayama disease. *Joint Bone Spine* 78: 316-318, 2011.
6. Furukawa Y, Iwasa K, Ono K, Yamada M. Fisher syndrome associated with immune thrombocytopenic purpura. *Intern Med* 50: 631-633, 2011.
7. Sakai K, Ono K, Ohta K, Yamada M. Progression of cerebrovascular lesions in pneumococcal meningitis. *Intern Med* 49: 1261-1262, 2010.
8. Ikeda T, Noto D, Noguchi-Shinohara M, Ono K, Takahashi K, Ishida C, Yoshita M, Kawaguchi M, Kawahara M, Iwasa K, Tomita K and Yamada M. CSF tau protein is a

useful marker for effective treatment of superficial siderosis of the central nervous system: two case reports. *Clin Neurol Neurosurg* 112: 62-64, 2010.

9. Morinaga A, Ono K, Komai K, Yamada M. Microscopic polyangitis presenting with temporal arteritis and multiple cranial neuropathies. *J Neurol Sci* 256: 81-83, 2007.
10. Motozaki Y, Komai K, Hirohata M, Asaka T, Ono K, Yamada M. Hereditary inclusion body myopathy with a novel mutation in the GNE gene associated with proximal leg weakness and necrotizing myopathy. *Eur J Neurol* 14: e14-e15, 2007.
11. Nozaki I, Hamaguchi T, Noguchi-Shinohara M, Ono K, Shirasaki H, Komai K, Kitamoto T, Yamada M. The MM2-cortical form of sporadic Creutzfeldt-Jakob disease presenting with visual disturbance. *Neurology* 67: 531-533, 2006.
12. Ono K, Iwasa K, Shirasaki H, Takamori M. Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report. *J Clin Neurosci* 10: 386-389, 2003.
13. Ono K, Komai K, Ikeda T. Dyke-Davidoff-Masson syndrome manifested by seizure in late childhood: a case report. *J Clin Neurosci* 10: 367-371, 2003.
14. Ono K, Komai K, Yamada M. Myoclonic involuntary movement associated with chronic manganese poisoning. *J Neurol Sci* 199: 93-96, 2002.

＜英文総説＞

1. Yamada M, Ono K, Hamaguchi T, Noguchi-Shinohara M. Natural Phenolic Compounds as Therapeutic and Preventive Agents for Cerebral Amyloidosis. *Adv Exp Med Biol* 863: 79-94, 2015.
2. Varghese M, Ho L, Wang J, Zhao W, Levine S, Ono K, Mannino S, Pasinetti GM. Green coffee as a novel agent for Alzheimer's disease prevention by attenuating diabetes. *Translational Neuroscience* 5, 111-116, 2014.
3. Ono K & Yamada M. Vitamin A and Alzheimer's disease. *Geriatr Gerontol Int* 12: 180-188, 2012
4. Ono K & Yamada M. Low-n oligomers as therapeutic targets of Alzheimer's disease. *J Neurochem* 117: 19-28, 2011.

5. Hamaguchi T, Ono K, Yamada M. Curcumin and Alzheimer's disease. *CNS Neurosci Ther* 16: 285-297, 2010.
6. Morinaga A, Ono K, Yamada M. New therapeutic strategy for amyloidosis. *Future Neurol* **4:** 287-289, 2009.
7. Ono K, Hirohata M, Yamada M.α-synuclein assembly as a therapeutic target of Parkinson's

disease and related disorders. *Curr Pharm Des* 14: 3247-3266, 2008.

8. Yamin G, Ono K, Inayathullah M, Teplow D.B. Amyloid β-protein assembly as therapeutic target of Alzheimer's disease. *Curr Pharm Des* 14: 3231-3246, 2008.
9. Hirohata M, Ono K, Yamada M. Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. *Curr Pharm Des* 14: 3280-3294, 2008.
10. Ono K, Naiki H, Yamada M. The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of β-amyloid fibrils (fAβ), as well as destabilize preformed fAβ. *Curr Pharm Des* 12: 4357-4375, 2006.
11. Ono K, Hamaguchi T, Naiki H, Yamada M. Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. *Biochim Biophys Acta (Molecular Basis of Disease)* 1762: 575-586, 2006.
12. Hamaguchi T, Ono K, Yamada M. Anti-amyloidgenic agents: implications for prevention and treatment of Alzheimer's disease. *Cell Mol Life Sci* 63: 1538-1552, 2006.

＜英文著書＞

1. Rosensweig C, Ono K, Murakami K, Lowenstein D, Bitan G, Teplow DB. Preparation of stable amyloid β-protein oligomers of defined assembly order. In: Sigurdsson EM, Calero M, Gasset M, eds. *Methods Mol Biol.* Humana Press, 489: pp23-31, 2012.
2. Pasinetti GM, Bilski A, Ho L, Wang J, Ferruzzi M, Yamada M, Ono K. Of Sound Mind and Body: Dietary Lifestyles, Promotion of Healthy Brain Aging and Prevention of Dementia in Healthy Individuals. In: Farooqui AA, Farooqui T, eds. *Metabolic Syndrome and Neurological Disorders.* Wiley-Blackwell Publishers, pp179-189, 2013.
3. Ono K, Noguchi-Shinohara M, Samuraki M, Matsumoto Y, Yanase D, Iwasa K, Naiki H and Yamada M. Cerebrospinal fluid and plasma of Alzheimer patients promote β-amyloid fibril formation in vitro. In: Skinner M, Berk JL, Connors LH, Seldin DC, eds. *XIth International Symposium on Amyloidosis*. Boca Raton, Taylor & Francis Group, pp25-26, 2007.

＜和文症例報告＞

1. 小野賢二郎，東馬康郎，吉田光宏，高守正治．頭部 MRI にて初期像を捉えたと思われた多形膠芽腫の 1 例．脳と神経 52：325-329，2000.

2. 小野賢二郎，山口和由，中村三郎，池田孝之，駒井清暢．血漿 VEGF 高値を示し，ステロイドが有効であった多発神経炎の 1 例．神経内科 52：123-125，2000.

3. 小野賢二郎，中村三郎，池田孝之，藤永康成．再発性脳梗塞を契機に確認された subclavian steal phenomenon の 1 例．神経内科 52：523-527，2000.

4. 小野賢二郎，瀧沢泰樹，駒井清暢，高守正治．前脊髄動脈症候群における MRI 所見の変化．臨床神経 38：806-810，1998.

5. 小野賢二郎，瀧沢泰樹，駒井清暢，新田永俊，高守正治．骨格筋 MRI が診断に有用であった封入体筋炎の 1 例．臨床神経 38：468-470，1998.

＜和文総説＞

1. 小野賢二郎，山田正仁．病態に基づいた Alzheimer 病の予防・治療薬の開発．神経治療学 32：169-172，2015.
2. 佐村木美晴, 小野賢二郎, 山田正仁. 血管性認知症. 認知症の最新医療 4: 170-172, 2014.
3. 小野賢二郎，山田正仁，樋口京一：脳アミロイドーシス：病態と伝播．日本認知症学会誌 28: 267-274, 2014.
4. 小野賢二郎, 山田正仁. パーキンソン病のバイオマーカー. 神経内科 81: 257-261, 2014.
5. 小野賢二郎，山田正仁．α-シヌクレイノパチーにおける血中及び骨髄中の神経疾患における α-シヌクレイン測定．臨床病理 62: 241-245, 2014.
6. 小野賢二郎.〈第 10 回　金沢大学十全医学賞受賞論文〉 フェノール化合物に焦点をあてたアルツハイマー病の予防・治療薬の開発. 十全医学会雑誌 122: 109-113, 2013.
7. 小野賢二郎，山田正仁．アルツハイマー病の根本的治療薬最前線－治療薬開発はどこまで進んできているのか「Aβ 凝集制御薬の開発」. 認知症の最新医療 10: 128-132, 2013.
8. 佐村木美晴，小野賢二郎，山田正仁：新しいアルツハイマー病診断基準に基づくアルツハイマー病の診断．認知症の最新医療 10: 147-149, 2013.
9. 小野賢二郎，山田正仁．バイオマーカーとしての α シヌクレイン．臨床神経 53: 983-985, 2013.
10. 小野賢二郎，山田正仁．ビタミン A とアルツハイマー病．イルシー115: 3-7, 2013.
11. 小野賢二郎，山田正仁．アルツハイマー病の未来　疾患修飾薬の開発研究の基礎．からだの科学 278: 152-155, 2013.
12. 小野賢二郎. アルツハイマー病 β アミロイド蛋白凝集機構解明から予防・治療薬開

発へ．十全医学会雑誌 122: 7-10, 2013.
13. 佐村木美晴，小野賢二郎，山田正仁．認知症診断に役立つ臨床検査 ：最新の検査を理解するために「PET」．認知症の最新医療 2: 22-26, 2012.
14. 小野賢二郎，山田正仁．認知症の阻止を狙った治療薬開発研究「Aβ 凝集機構解明から予防・治療薬開発へ」．日本認知症学会誌 26:1-6, 2012.
15. 小野賢二郎, 山田正仁. アルツハイマー病の予防. 認知症の最新医療（創刊号）1: 24-27, 2011.
16. 小野賢二郎. アルツハイマー病βアミロイド蛋白凝集過程における分子間相互作用. 神経化学 49: 933-943, 2010.
17. 小野賢二郎，山田正仁．アルツハイマー病患者の脳脊髄液はβアミロイド線維形成を促進する．老年期認知症研究誌 16: 115-117, 2010.
18. 小野賢二郎，山田正仁．Aβ 凝集阻害薬．Progress in Medicine 30: 2149-2152, 2010.
19. 小野賢二郎，山田正仁．Aβ 凝集の分子機構と治療．Pharma Medina 28: 51-54, 2010.
20. 内木宏延，長谷川一浩，小野賢二郎，山田正仁．アミロイド線維形成の重合核依存性重合モデルと線維形成阻害薬の探索．Yakugaku Zasshi 130: 503-509, 2010.
21. 小野賢二郎，山田正仁．限局性アミロイドーシスー特に脳アミロイドーシスについて．血液 19: 51-55, 2009.
22. 小野賢二郎，山田正仁．Aβ 凝集機序とその制御．医学のあゆみ（特集　アミロイドーシスの診療　UPDATE）229: 405-408, 2009.
23. 篠原もえ子，小野賢二郎，山田正仁．アルツハイマー病：脳脊髄液検査（Aβ，タウ以外）．日本臨床 66（増刊号 1）: 237-240, 2008.

24. 小野賢二郎，山田正仁．βアミロイドの凝集とその抑制薬．腎と透析（特集　アミロイドーシスの診療 up to date）62: 260-262, 2007.
25. 小野賢二郎，山田正仁．β アミロイドの凝集とその抑制薬．医学のあゆみ（特集 Alzheimer 病− 基礎・臨床研究の最新動向）220: 361-364, 2007.
26. 廣畑美枝，小野賢二郎，山田正仁．NSAIDs の抗 Alzheimer 病効果．神経治療 24: 187-194, 2007.
27. 小野賢二郎，濱口毅，山田正仁．抗加齢サプリメントの認知機能改善効果；アンチエイジングサプリメントの認知機能に対する効果．コエンザイム Q10 など．老年精神医学雑誌 17: 58-62, 2006.

28. 小野賢二郎，山田正仁：痴呆症治療をめぐる戦略；現状と可能性，課題を考える．2. 近未来に向けて解決すべき治療・予防戦略□□□(2) Aβ 凝集を介した治療アプローチの現状と課題．老年精神医学雑誌（増刊号） 16: 111-115, 2005.
29. 小野賢二郎，山田正仁．アルツハイマー病βアミロイドに対する赤ワイン関連ポリフェノールの効果．Medical Technology 32：121-122，2004.
30. 小野賢二郎，山田正仁．アルツハイマー病βアミロイド線維形成機構解明から治療薬開発へ．昭和医学会雑誌 64: 373-397, 2004.
31. 小野賢二郎，駒井清暢，山田正仁．前脊髄動脈症候群の経時的 MRI．神経内科 53(Suppl.2)：224-225，2000.

＜和文著書＞

1. 小野賢二郎，山田正仁．抗認知症薬使用に際して注意すべき副作用があったら教えてください。川畑信也（編） 治療特別編集 認知症でお困りですか？− かかりつけ医のギモンにお答えします。南山堂，東京，pp116-118， 2013.
2. 小野賢二郎，山田正仁．β アミロイド凝集過程と阻害薬開発．アミロイドーシス診療の全て ガイドライン完全詳解，医歯薬出版，東京，pp183-190, 2011.
3. 小野賢二郎．Parkinson’s disease and other movement disorders．L. Ginsberg 著 若山吉弘 監訳 神経内科レクチャーノート，シュプリンガージャパン，東京，pp88-98, 2007.
4. 小野賢二郎, 山田正仁. アルツハイマー病. 医学生・研修医のための病態生理 FIRST AID, pp503-505, 2007.
5. 小野賢二郎，山田正仁．慢性硬膜下血腫．医学生・研修医のための病態生理 FIRST AID，pp524-525, 2007.
6. 小野賢二郎，山田正仁．アルツハイマー病．EBM のためのベストアプローチ臨床検査実践ガイド，pp143, 2006.
7. 小野賢二郎，山田正仁．てんかん．EBM のためのベストアプローチ臨床検査実践ガイド，pp142, 2006.
8. 小野賢二郎，山田正仁．エンドセリン変換酵素(ECE)．日本臨床−痴呆症学 1（別冊）pp46-48，2003.

＜その他＞

1. 小野賢二郎. 学会印象記　Alzheimer's Association International Conference 2013. *BRAIN and NERVE* 65: 1414-1415, 2013.